Balyasny Asset Management’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-189,165
| Closed | -$16.1M | – | 1691 |
|
|
2019
Q4 | $16.1M | Buy |
+189,165
| New | +$12.6M | 0.1% | 311 |
|
|
2019
Q3 | – | Sell |
-129,837
| Closed | -$4.74M | – | 1776 |
|
|
2019
Q2 | $4.74M | Buy |
+129,837
| New | +$4.24M | 0.03% | 621 |
|
|
2019
Q1 | – | Sell |
-53,888
| Closed | -$1.27M | – | 1782 |
|
|
2018
Q4 | $1.03M | Buy |
+53,888
| New | +$1.25M | 0.01% | 891 |
|
|
2018
Q3 | – | Sell |
-85,186
| Closed | -$3.21M | – | 2218 |
|
|
2018
Q2 | $3.13M | Sell |
85,186
-87,879
| -51% | -$2.86M | 0.01% | 803 |
|
|
2018
Q1 | $5.7M | Buy |
+173,065
| New | +$5.41M | 0.02% | 671 |
|
|
2017
Q2 | – | Sell |
-8,800
| Closed | -$392K | – | 1891 |
|
|
2017
Q1 | $430K | Buy |
+8,800
| New | +$401K | ﹤0.01% | 1322 |
|
|
2016
Q4 | – | Sell |
-219,305
| Closed | -$8.28M | – | 1551 |
|
|
2016
Q3 | $8.28M | Buy |
219,305
+60,605
| +38% | +$2.28M | 0.05% | 425 |
|
|
2016
Q2 | $5.34M | Buy |
158,700
+150,531
| +1,843% | +$5.31M | 0.03% | 490 |
|
|
2016
Q1 | $260K | Sell |
8,169
-155,885
| -95% | -$5.09M | ﹤0.01% | 1041 |
|
|
2015
Q4 | $6.13M | Buy |
+164,054
| New | +$6.2M | 0.04% | 467 |
|
|
2013
Q4 | – | Sell |
-331,600
| Closed | -$11.1M | – | 697 |
|
|
2013
Q3 | $11.1M | Buy |
+331,600
| New | +$10.6M | 0.15% | 182 |
|
Other funds holding MDCO
Balyasny Asset Management's MDCO Position: Q1 2020 in Review
Balyasny Asset Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 189,165 shares — an estimated $16.1M sold.
Balyasny Asset Management first reported a position in MDCO in Q3 2013 and held it in 11 quarters. The position peaked at $16.1M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Balyasny Asset Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Balyasny Asset Management sold 189,165 Medicines Co shares in Q1 2020, an estimated $16.1M.
- Balyasny Asset Management first reported a position in Medicines Co in Q3 2013 and held it in 11 quarters.
- Balyasny Asset Management's Medicines Co position peaked at $16.1M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Balyasny Asset Management's 13F filing for Q1 2020, filed 15 May 2020.